Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Pierre Benite – page 40

649 clinical trials in Pierre Benite, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Pierre Benite at a glance
649
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

649 trials in Pierre Benite

Open in trial search

Study of Olaparib and Abiraterone for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:AstraZeneca AB

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALKYLATING AGENTS
  • Sponsor:Geron Corp.

Cervix carcinoma

Not recruiting

Study of LN-145 (tumor infiltrating lymphocytes) with cyclophosphamide, fludarabine, and aldesleukin in patients with recurrent, metastatic, or persistent cervical cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Iovance Biotherapeutics Inc.

Giant cell arteritis

Not recruiting

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Folic Acid
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Plasma cell myeloma+1

Not recruiting

Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Neoplasm

Not recruiting

Study of DF6002 alone and combined with nivolumab in patients with advanced solid tumors: A safety and effectiveness trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Df6002
  • Sponsor:Dragonfly Therapeutics Inc.

Study on the Safety and Effects of IPH6501 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Iph6501
  • Sponsor:Innate Pharma

Study of Azenosertib (ZN-c3) for Women with Recurrent or Persistent Uterine Serous Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:K-Group Beta Inc.

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study on Teclistamab and Drug Combination for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Follicular lymphoma

Not recruiting

Study of Zanubrutinib and Obinutuzumab for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Beigene Ltd.

Study of Tamibarotene, Venetoclax, and Azacitidine for Adults with RARA-positive Acute Myeloid Leukemia Not Eligible for Standard Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Syros Pharmaceuticals Inc.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Pierre Benite

What the registry says about research in the country

01 Infectious Diseases Research

Innovative clinical trials focusing on vaccine development against major viral infections. Studies include evaluations of new treatments for influenza, cytomegalovirus, and yellow fever.

  • Novel influenza vaccine efficacy testing
  • CMV prevention strategies
  • Yellow fever vaccine comparison studies

Research aims to enhance prevention and protection against these significant viral threats.

02 Gastrointestinal Disorders

Groundbreaking research in inflammatory bowel diseases, exploring innovative therapeutic approaches including fecal microbiota transplantation for both Crohn's disease and ulcerative colitis.

  • Crohn's disease treatment alternatives
  • Ulcerative colitis management
  • Microbiome-based interventions

Studies focus on developing alternative treatment strategies for patients with limited therapeutic options.

03 Oncology and Hematology

Comprehensive research into blood cancers and solid tumors, including multiple myeloma, leukemia, and advanced prostate cancer. Trials evaluate novel therapeutic combinations and targeted treatments.

  • Multiple myeloma treatment innovations
  • Prostate cancer therapy advancement
  • Leukemia treatment strategies

Focus on developing more effective and personalized treatment approaches.

04 Cardiovascular and Metabolic Disease

Studies addressing heart failure prevention, chronic kidney disease, and metabolic disorders. Research includes evaluation of novel drug combinations and therapeutic strategies.

  • Heart failure risk reduction
  • Kidney disease management
  • Obesity treatment studies

Emphasis on preventing disease progression and improving patient outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.